Skip to main content
. Author manuscript; available in PMC: 2021 Apr 26.
Published in final edited form as: Biochem Pharmacol. 2020 Oct 2;182:114253. doi: 10.1016/j.bcp.2020.114253

Fig. 2.

Fig. 2.

Promising Drugs for targeting OXPHOS dependent AML cells and LSCs [46,48,55–57,67,71,73,75,76]. Some AML cells and LSCs rely on OXPHOS to supply ATP for basic cellular functions and survival. This is a unique target for novel therapies such as ONC201, ONC212, IACS-010759 and ME-344. IACS-010759 and ME-344 suppress OXPHOS by directly targeting complexes of the ETC. While IACS-010759 has been shown to inhibit the activity of complex I, ME-344 can repress the contribution of both complex I and complex III to OXPHOS. On the other hand, ONC201 and ONC212 target the general functionality of mitochondria in AML cells through activation of the mitochondrial protease ClpP, ultimately leading to mitochondrial dysfunction and cell death.